DaVita HealthCare Partners Inc. (DVA) Downgraded by J P Morgan Chase & Co

DaVita HealthCare Partners Inc. (NYSE:DVA) was downgraded by J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating in a research report issued on Monday, October 9th, MarketBeat.com reports.

Several other research firms have also commented on DVA. TheStreet lowered shares of DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised shares of DaVita HealthCare Partners from a “sell” rating to a “hold” rating in a report on Thursday, August 3rd. Jefferies Group LLC reissued a “hold” rating and issued a $70.00 target price on shares of DaVita HealthCare Partners in a report on Thursday, August 3rd. Royal Bank Of Canada reissued a “hold” rating and issued a $64.00 target price on shares of DaVita HealthCare Partners in a report on Wednesday, September 6th. Finally, BidaskClub lowered shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Saturday, July 8th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. DaVita HealthCare Partners currently has a consensus rating of “Hold” and a consensus price target of $65.00.

Shares of DaVita HealthCare Partners (NYSE DVA) opened at 59.35 on Monday. DaVita HealthCare Partners has a 1-year low of $53.58 and a 1-year high of $70.16. The stock’s 50 day moving average is $58.32 and its 200 day moving average is $62.55. The company has a market capitalization of $11.35 billion, a PE ratio of 9.04 and a beta of 0.90.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 1st. The company reported $0.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the prior year, the firm earned $1.01 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities research analysts anticipate that DaVita HealthCare Partners will post $3.59 EPS for the current fiscal year.

DaVita HealthCare Partners announced that its Board of Directors has initiated a share repurchase program on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: This piece was reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/davita-healthcare-partners-inc-dva-downgraded-to-underweight-at-j-p-morgan-chase-co/1703966.html.

A number of institutional investors and hedge funds have recently modified their holdings of DVA. BlackRock Inc. lifted its position in DaVita HealthCare Partners by 2,315.8% in the first quarter. BlackRock Inc. now owns 12,892,477 shares of the company’s stock worth $876,303,000 after buying an additional 12,358,806 shares during the last quarter. Park West Asset Management LLC lifted its position in DaVita HealthCare Partners by 88.8% in the first quarter. Park West Asset Management LLC now owns 1,856,516 shares of the company’s stock worth $126,187,000 after buying an additional 873,064 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in DaVita HealthCare Partners in the first quarter worth $31,376,000. PGGM Investments bought a new stake in DaVita HealthCare Partners in the second quarter worth $28,598,000. Finally, Highbridge Capital Management LLC lifted its position in DaVita HealthCare Partners by 45,626.9% in the first quarter. Highbridge Capital Management LLC now owns 364,215 shares of the company’s stock worth $24,756,000 after buying an additional 365,015 shares during the last quarter. Institutional investors own 83.23% of the company’s stock.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.